Patent intelligence · US
US 9694079
Long-acting polymeric delivery systems
Long-acting polymeric delivery systems
Patent details — US 9694079
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 4, 2017
- Expiration
- Jun 29, 2037
- Applicant
- Heron Therapeutics, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/00, A61K31/167, A61K31/196
Quick answer
US 9694079 (Long-acting polymeric delivery systems) is held by Heron Therapeutics, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Heron Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/00, A61K31/167, A61K31/196, A61K31/245, A61K31/445
More from Heron Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11413350
Long-acting polymeric delivery systems
granted
Frequently asked questions
What is US patent 9694079?
US 9694079 (Long-acting polymeric delivery systems) is held by Heron Therapeutics, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9694079?
Heron Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.
When does US 9694079 expire?
Our index shows an expiration date of Jun 29, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.